Mitochondrial DNA Depletion Induces Radioresistance by Suppressing G2 Checkpoint Activation in Human Pancreatic Cancer Cells
Overview
Authors
Affiliations
We hypothesized that mitochondrial function regulates cell cycle checkpoint activation and radiosensitivity. Human pancreatic tumor cells (MiaPaCa-2, rho(+)) were depleted of mitochondrial DNA (rho degrees ) by culturing cells in the presence of ethidium bromide. Depletion of mitochondrial DNA was verified by PCR amplification of total DNA using primer pairs specific for mitochondrial DNA. Loss of mitochondrial DNA decreased plating efficiency and the percentage of cells in S phase. Exponential cultures were irradiated with 2, 4 and 6 Gy (dose rate: 0.83 Gy/min) of ionizing radiation and harvested for determination of cell viability, growth and cell cycle phase distributions. Rho degrees cells were radioresistant compared to rho(+) cells, with a dose-modifying factor (DMF) of 1.6. Although cell growth was significantly inhibited in irradiated rho(+) cells compared to unirradiated control cells, the inhibition in Rho degrees cells was minimal. In addition, mitochondrial DNA depletion suppressed radiation-induced G(2) checkpoint activation, which was accompanied by increases in both cyclin B1 and CDK1. These results suggest that mitochondrial function may regulate cell cycle checkpoint activation and radiosensitivity in pancreatic cancer cells.
Leonov S, Dorfman A, Pershikova E, Inyang O, Alhaddad L, Wang Y Cancers (Basel). 2024; 16(12).
PMID: 38927940 PMC: 11201585. DOI: 10.3390/cancers16122235.
The promising role of miRNAs in radioresistance and chemoresistance of nasopharyngeal carcinoma.
Xu H, Li W, Wang D Front Oncol. 2024; 14:1299249.
PMID: 38482204 PMC: 10933132. DOI: 10.3389/fonc.2024.1299249.
OLeary B, Kalen A, Pope A, Goswami P, Cullen J Radiat Res. 2023; 200(5):444-455.
PMID: 37758045 PMC: 10699322. DOI: 10.1667/RADE-22-00182.1.
Tamoxifen induces radioresistance through NRF2-mediated metabolic reprogramming in breast cancer.
Reinema F, Sweep F, Adema G, Peeters W, Martens J, Bussink J Cancer Metab. 2023; 11(1):3.
PMID: 36755288 PMC: 9909892. DOI: 10.1186/s40170-023-00304-4.
Miller C, Xu F, Zhao Y, Luo W, Zhong W, Meyer K Antioxidants (Basel). 2022; 11(11).
PMID: 36358489 PMC: 9686922. DOI: 10.3390/antiox11112119.